$XOMA

Sitko Bradley sold (to issuer) 7,358 shares of XOMA

Sitko Bradley (Chief Investment Officer) sold (to issuer) 7,358 shares of XOMA Royalty Corp (XOMA) across 2 trades on 2026-07-14.

Original reporting
SEC EDGAR · Sitko Bradley
Published Jul 15, 2026, 1:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 2:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$XOMA
Neutral
medium confidence
Mentioned
$XOMA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XOMANeutralLow
01

Why it matters

The disclosure updates insider ownership (ending with 0 shares) but does not provide a fundamental driver such as earnings, guidance, trial results, or a corporate transaction.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to materially change valuation expectations.

03

What to watch

No sale price is disclosed, and the absence of a 10b5-1 plan does not, by itself, establish intent or future trading behavior.

Relevance 3/10Novelty 3/10Timing: immediately after the 2026-07-14 Form 4 filing

Background

This is an SEC Form 4 insider transaction for XOMA Royalty Corp, reported by Sitko Bradley (Chief Investment Officer).

Company-level read

Ticker impact

$XOMANeutralMedium confidence
Context

XOMA disclosed an insider sale by CIO Sitko Bradley of 7,358 shares to the issuer on 2026-07-14, with zero shares remaining.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, but the article provides no sale price, no 10b5-1 plan, and the transaction is not tied to a fundamental corporate event.

Market effects

No clear sector read-through from a single insider sale without additional corporate or clinical catalysts.

None indicated.

None indicated.

Counterpoint

The sale is to the issuer (often buyback-related mechanics) and may be administrative or liquidity-driven rather than a bearish view.

Key entities

  • XOMA Royalty Corp

    Company that filed the Form 4 insider transaction.

  • Sitko Bradley

    Chief Investment Officer who sold 7,358 shares to the issuer.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LGNDMedAI 9/10

XOMA Royalty Announces Closing of Its Acquisition by Ligand

XOMA Royalty said Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty. Under the April 27 deal, XOMA shareholders received $39.00 cash per share and one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation. XOMA shares no longer trade on Nasdaq.

$LAURMed

Snow Ian Kendell sold $19.1M of LAUR (indirect holdings)

Snow Ian Kendell sold 521,229 indirectly-held shares of LAUREATE EDUCATION, INC. (LAUR) at an average of $36.65 ($36.26–$38.43, $19.10M total) across 3 trades over 2026-08-31 to 2026-09-02. Filed jointly with Snow Phipps Group (RPV), L.P. (Director), Snow Phipps Group (Offshore), L.P. (Director), SPG Co-Investment, L.P. (Director), Snow Phipps Group (B), L.P. (Director), Snow Phipps Group, L.P. (Director) and Snow Phipps Group, LLC (Director).